(6-(4-bromophenyl)-2-methylpyrimidin-4-yl)(5-isopropyl-2,3,4-trimethoxyphenyl)methanone | 1527481-34-0

• 分子结构分类: 有机化合物
• 英文名称: (6-(4-bromophenyl)-2-methylpyrimidin-4-yl)(5-isopropyl-2,3,4-trimethoxyphenyl)methanone
• CAS: 1527481-34-0
• 化学式: C₂₄H₂₅BrN₂O₄
• 分子量: 485.377
• InChiKey: CUAFNWLNRWEGBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.59
• 重原子数：
  31.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.54
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (6-(4-bromophenyl)-2-methylpyrimidin-4-yl)(5-isopropyl-2,3,4-trimethoxyphenyl)methanone 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以21%的产率得到[6-(4-Bromophenyl)-2-methylpyrimidin-4-yl]-(2,3,4-trihydroxy-5-propan-2-ylphenyl)methanone
  参考文献：
  名称：

  Synthesis of new mixed phenol/heterocyclic derivatives and studies of their activity as inhibitors of Bax/Bcl-xL interaction

  摘要：

  We describe here the synthesis of a series of new molecules containing phenol and heteroaromatic moieties, compounds, which have been evaluated for their ability to inhibit Bax/Bcl-xL interactions in BRET assays. Among them, a triazole derivative 13, exhibit a very promising activity, being more potent than the reference compounds acylpyrogallol 1 and ABT 737. These preliminary results demonstrate that derivatives of this family can be attractive to develop new molecules with potent anticancer activity. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.11.060
• 作为产物：
  描述：

  1-(4-bromophenyl)-4-((tert-butyldimethylsilyl)oxy)-4-(5-isopropyl-2,3,4-trimethoxyphenyl)but-2-yn-1-ol 在 四丁基氟化铵 、 sodium carbonate 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 氯仿 、 二甲基亚砜 、 乙腈 为溶剂， 反应 6.5h， 生成 (6-(4-bromophenyl)-2-methylpyrimidin-4-yl)(5-isopropyl-2,3,4-trimethoxyphenyl)methanone
  参考文献：
  名称：

  Synthesis of new mixed phenol/heterocyclic derivatives and studies of their activity as inhibitors of Bax/Bcl-xL interaction

  摘要：

  We describe here the synthesis of a series of new molecules containing phenol and heteroaromatic moieties, compounds, which have been evaluated for their ability to inhibit Bax/Bcl-xL interactions in BRET assays. Among them, a triazole derivative 13, exhibit a very promising activity, being more potent than the reference compounds acylpyrogallol 1 and ABT 737. These preliminary results demonstrate that derivatives of this family can be attractive to develop new molecules with potent anticancer activity. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.11.060